daytrade diaries... december 3, page-109

VHL

The granting of fast-track status for
TG4010 is significant for the potential future success of the product. This recognition by the FDA confirms the importance
of the product in a very large market area of unmet medical need. Peak sales for such a NSCLC product have been
estimated at over USD 1 billion per annum. The fast track status will also shorten the time required for TG4010 to reach
the market”.
Transgene’s Chief Executive Officer, Philippe Archinard is noted as saying “We are actively preparing the next
development steps for the product and look forward to working closely with the FDA. Discussions for the partnering of
TG4010 have progressed and we hope to reach a collaborative agreement around year-end 2009”.
Virax’s Co-X-Gene™ sub licence provides that a percentage of milestone moneys received by Transgene are payable to
Virax.